Inventiva To Present Data From The Final Analysis Of The Phase 2 Study Evaluating The Combination Of Lanifibranor With Empagliflozin In Patients With Mash And T2D At The AASLD The Liver Meeting Late-Breaker Session; 50% Percent Of Patients Saw Their...
Inventiva To Present Data From The Final Analysis Of The Phase 2 Study Evaluating The Combination Of Lanifibranor With Empagliflozin In Patients With Mash And T2D At The AASLD The Liver Meeting Late-Breaker Session; 50% Percent Of Patients Saw Their...
Inventiva To Present Data From The Final Analysis Of The Phase 2 Study Evaluating The Combination Of Lanifibranor With Empagliflozin In Patients With Mash And T2D At The AASLD The Liver Meeting Late-Breaker Session; 50% Percent Of Patients Saw Their HbA1c Levels Below 6.5% At Week 24 Following Treatment With Lanifibranor Alone Or In Combination With Empagliflozin
Inventiva將在AASLD肝病年會晚點研討會上展示來自第2期研究最終分析的數據，評估Lanifibranor與Empagliflozin聯合治療Mash和T2D患者；在第24周根據Lanifibranor單獨或與Empagliflozin聯合治療後，50%的患者HbA1c水平降至6.5%以下。
- Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 in San Diego.
- LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.
- 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin.
- 58% of patients on lanifibranor alone and 80% of those on the combination therapy had a decrease of at least 1% in HbA1c at week 24, compared to 0% in the placebo group.
- Liver function tests, markers of liver fibrosis and markers or cardiometabolic health including HOMA-IR, hsCRP, ferritin, lipid profile and adiponectin levels were also improved with lanifibranor alone or in combination with empagliflozin.
- The weight gain observed in a proportion of patients under lanifibranor was not observed in patients treated with the combination of lanifibranor with empagliflozin.
- 數據將於2024年11月18日星期一作爲美國肝病研究協會(AASLD)肝病年會上的晚點報告海報在聖地亞哥展示。
- LEGEND在降低HbA1c水平方面實現了主要療效終點，與安慰劑相比，Lanifibranor組和Lanifibranor與Empagliflozin組均顯著降低HbA1c水平。
- 在第24周，50%的患者在Lanifibranor單獨或與Empagliflozin聯合治療後，其HbA1c水平降至6.5%以下。
- 在第24周，使用Lanifibranor單獨治療的患者中有58%，聯合治療的患者中有80%的患者HbA1c降低至少1%，而安慰劑組爲0%。
- 肝功能測試、肝纖維化標誌物以及心臟代謝健康標誌物，包括HOMA-IR、hsCRP、鐵蛋白、脂質譜和脂聯素水平在使用Lanifibranor單獨或與Empagliflozin聯合治療後也有所改善。
- 部分Lanifibranor患者觀察到體重增加，而使用Lanifibranor與Empagliflozin聯合治療的患者沒有觀察到這種情況。
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the presentation of the final analysis of LEGEND, Phase 2 proof-of-concept clinical trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The data will be presented Monday November 18, 2024, as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place in San Diego California.
2024年11月15日，位於法國戴克和美國紐約長島城的Inventiva（Euronext巴黎和Nasdaq: IVA）,一家專注於開發口服小分子治療代謝功能障礙型脂肪肝(MASH)即非酒精性脂肪肝(NASH)等疾病的臨床生物製藥公司，今日宣佈LEGEND第2期概念臨床試驗的最終分析結果，評估Lanifibranor與Empagliflozin聯合治療MASH和2型糖尿病（T2D）患者的數據。數據將於2024年11月18日星期一在美國肝病研究協會(AASLD)肝病年會上作爲晚點報告海報發佈，該會議將在加利福尼亞州聖地亞哥舉行。
譯文內容由第三人軟體翻譯。
